# Mirikizumab PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/mirikizumab

> The next catalyst for mirikizumab, sponsored by ELI LILLY & Co (LLY), is its primary completion, December 2027.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, month only, quarter only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Key facts

| Field | Value |
| --- | --- |
| Drug | mirikizumab |
| Codes | LY3074828 |
| Sponsor | ELI LILLY & Co (LLY) https://sec-api.dev/companies/lly/catalysts |
| Indications | [Ulcerative Colitis](https://sec-api.dev/indications/ulcerative-colitis), [Crohn's Disease](https://sec-api.dev/indications/crohn-s-disease) |
| Modality |  |
| FDA designations | none disclosed |

## Timeline

### March 4, 2026: primary completion

- Status: completed. Date confidence: exact. Stage: 3. Indication: Ulcerative Colitis.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT03519945 (A Study to Evaluate the Long-Term Efficacy and Safety of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 3)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-03-04 (ACTUAL); Lead Sponsor Eli Lilly and Company." https://clinicaltrials.gov/study/NCT03519945

### December 2027: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: Crohn's Disease.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT05509777 (A Study of Mirikizumab (LY3074828) in Pediatric Participants With Crohn's Disease): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-12 (ESTIMATED); Lead Sponsor Eli Lilly and Company." https://clinicaltrials.gov/study/NCT05509777

### Dec 2027 to Mar 2028: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Crohn's Disease.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT05509777 (A Study of Mirikizumab (LY3074828) in Pediatric Participants With Crohn's Disease): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-12 (ESTIMATED); Lead Sponsor Eli Lilly and Company." https://clinicaltrials.gov/study/NCT05509777

## Same indication

- [ABBV-8736](https://sec-api.dev/pdufa/abbv-8736) (ABBV)
- [ABX464](https://sec-api.dev/pdufa/abx464) (ABVX)
- [AMJEVITA® (adalimumab)](https://sec-api.dev/pdufa/adalimumab) (ABBV)
- [AZD7798](https://sec-api.dev/pdufa/azd7798) (AZN)
- [Brivekimig](https://sec-api.dev/pdufa/brivekimig) (SNY)
- [Darvadstrocel](https://sec-api.dev/pdufa/darvadstrocel) (TAK)
- [Duvakitug](https://sec-api.dev/pdufa/duvakitug) (SNY)
- [Eltrekibart](https://sec-api.dev/pdufa/eltrekibart) (LLY)
- [Emvistegrast](https://sec-api.dev/pdufa/emvistegrast) (GILD)
- [Etrasimod](https://sec-api.dev/pdufa/etrasimod) (PFE)
- [Tremfya (guselkumab)](https://sec-api.dev/pdufa/guselkumab) (JNJ)
- [Iv tulisokibart](https://sec-api.dev/pdufa/iv-tulisokibart) (MRK)
- [Mirikizumab iv](https://sec-api.dev/pdufa/mirikizumab-iv) (LLY)
- [Nx-13 250mg](https://sec-api.dev/pdufa/nx-13) (ABBV)
- [Obefazimod](https://sec-api.dev/pdufa/obefazimod) (ABVX)
- [Skyrizi® (risankizumab)](https://sec-api.dev/pdufa/risankizumab) (ABBV)
- [Risankizumab iv](https://sec-api.dev/pdufa/risankizumab-iv) (ABBV)
- [Risankizumab sc](https://sec-api.dev/pdufa/risankizumab-sc) (ABBV)
- [SAR441566](https://sec-api.dev/pdufa/sar441566) (SNY)
- [SPY001](https://sec-api.dev/pdufa/spy001) (SYRE)
- [Tilpisertib fosmecarbil](https://sec-api.dev/pdufa/tilpisertib-fosmecarbil) (GILD)
- [Zepbound (tirzepatide)](https://sec-api.dev/pdufa/tirzepatide) (LLY)
- [Xeljanz (tofacitinib citrate)](https://sec-api.dev/pdufa/tofacitinib) (PFE)
- [RINVOQ® (upadacitinib)](https://sec-api.dev/pdufa/upadacitinib) (ABBV)
- [Entyvio® (vedolizumab)](https://sec-api.dev/pdufa/vedolizumab) (TAK)
- [Vedolizumab iv](https://sec-api.dev/pdufa/vedolizumab-iv) (TAK)
- [Vedolizumab sc](https://sec-api.dev/pdufa/vedolizumab-sc) (TAK)
- [Zasocitinib](https://sec-api.dev/pdufa/zasocitinib) (TAK)
- [Zotemtegrast](https://sec-api.dev/pdufa/zotemtegrast) (LLY)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/mirikizumab.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Mirikizumab PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/mirikizumab

```bibtex
@misc{secapidev_pdufa_mirikizumab_20261116,
  title        = {Mirikizumab PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/mirikizumab}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_mirikizumab_20261116","title":"Mirikizumab PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/mirikizumab","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
